Abstract
Aleglitazar is a dual peroxisome proliferator-activated receptor a/? agonist in development for cardiovascular risk reduction in patients following an acute coronary syndrome (ACS) who have type 2 diabetes mellitus. Most ACS patients receive aspirin, which is associated with decreased glomerular
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
